Research Analysts Offer Predictions for Qiagen’s Q4 2025 Earnings (NYSE:QGEN)

Qiagen (NYSE:QGEN) – William Blair increased their Q4 2025 earnings per share (EPS) estimates for Qiagen in a note issued to investors on Wednesday, May 1st. William Blair analyst A. Brackmann now forecasts that the company will post earnings per share of $0.62 for the quarter, up from their previous forecast of $0.61. The consensus estimate for Qiagen’s current full-year earnings is $2.09 per share.

Several other research firms have also recently weighed in on QGEN. Citigroup reduced their target price on shares of Qiagen from $61.86 to $60.00 and set a “buy” rating for the company in a research note on Thursday, February 8th. Morgan Stanley upgraded Qiagen from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $49.48 to $51.00 in a research note on Friday, February 16th. JPMorgan Chase & Co. lifted their price target on shares of Qiagen from $50.00 to $52.00 and gave the stock an “overweight” rating in a research note on Thursday, February 8th. Finally, Stifel Nicolaus dropped their price target on shares of Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $50.95.

Qiagen Stock Performance

Shares of NYSE QGEN opened at $42.98 on Friday. The business’s 50 day moving average is $42.53 and its two-hundred day moving average is $42.75. The company has a market cap of $9.81 billion, a P/E ratio of 28.85, a P/E/G ratio of 3.61 and a beta of 0.42. The company has a quick ratio of 1.62, a current ratio of 1.84 and a debt-to-equity ratio of 0.25. Qiagen has a 12 month low of $34.74 and a 12 month high of $47.70.

Qiagen (NYSE:QGEN) last posted its earnings results on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. The business had revenue of $459.00 million for the quarter, compared to analyst estimates of $453.91 million. Qiagen had a net margin of 17.38% and a return on equity of 12.59%. Qiagen’s revenue was down 5.4% compared to the same quarter last year. During the same period last year, the business posted $0.53 EPS.

Hedge Funds Weigh In On Qiagen

A number of institutional investors and hedge funds have recently bought and sold shares of QGEN. Riverview Trust Co acquired a new position in shares of Qiagen during the first quarter worth approximately $28,000. Briaud Financial Planning Inc bought a new position in Qiagen in the 3rd quarter worth approximately $31,000. Tower Research Capital LLC TRC lifted its holdings in Qiagen by 66.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 710 shares of the company’s stock worth $31,000 after buying an additional 283 shares in the last quarter. Park Place Capital Corp bought a new position in Qiagen in the 1st quarter valued at $36,000. Finally, Quarry LP acquired a new stake in shares of Qiagen in the 4th quarter valued at $38,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.